IL2 and type 1 diabetes mellitus: Although RAPA was beneficial when administered alone [75,76], recent studies did not confirm synergistic action of both immunotherapeutics used in combination [18], thus demonstrating limitations of IL-2 and RAPA in the therapy of T1D.